Biotricity Inc. (Biotricity) today announced its patent filing for the company’s Bioheart device. Bioheart, regarded as one of the most innovative wearable heart monitoring solutions and recognized as one of TIME Magazine’s Best Inventions of 2022 stands as a “game changer” in the industries of personal heart and remote lifestyle monitoring. This patent safeguards Bioheart’s exclusive 3-view dry-contact technology, advanced sensor system, unique design, and compact form factor, a combination that’s never been seen in the consumer market.

Biotricity announces patent filing for cutting-edge Biotres device

October 3, 2023

Biotricity Inc. (Biotricity) today announced the filing of a patent application for its groundbreaking Biotres device. This patent protects Biotres’ proprietary 3 channel technology, multiple sensors, architecture and compact form factor, a combination that has never been done before. This filing expands the Company’s IP portfolio while increasing market barriers.

Biotricity, Healthcare

Biotricity unveils a new digital presence, highlighting its expanding technology portfolio and cutting-edge innovations

September 13, 2023

Biotricity Inc. (Biotricity)announced today the official launch a new digital presence that illustrates more completely the depth of Biotricity technologies and solutions. The company has built a suite of solutions that combine connectivity, smart analytics, AI and cutting-edge cloud technologies. The solutions support individuals and patients from diagnostics to disease management depending on the solution utilized.

Biotricity, News

Biotricity achieves $14 Million Revenue Run Rate in August 2023

August 30, 2023

Biotricity Inc. (Biotricity) today reported that it achieved a record $14 million annualized revenue run rate in August, extending its growth by over eight percent from the previously announced $13 million run rate. In its Corporate Impact Report published last spring, Biotricity described both “better patient outcomes and substantial cost savings” for patients using its devices.

Biotricity, Financial Results

Biotricity reports strong growth for its first quarter fiscal year 2024 and provides financial results and business updates

August 15, 2023

Biotricity Inc. (Biotricity) today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023. The company reported that the Q1-FY24 revenue grew by 46.9% YOY to $3.0 million, continuing to advance toward positive cashflow.

Biotricity, Healthcare, News

Biotricity expands its proprietary AI model and deepens relationship with Amazon AWS and Google’s tensor flow for remote cardiac care applications

July 25, 2023

Biotricity Inc. (Biotricity) today announced its strengthened relationships with Amazon and Google. The Company is expanding its AI technology development in remote cardiac care, leveraging its proprietary AI technology to provide a suite of predictive monitoring tools to enhance new disease profiling, improve patient management, and revolutionize the healthcare industry for disease prevention.

Biotricity, News

Biotricity regains Nasdaq listing compliance

July 21, 2023

Biotricity Inc. (Biotricity) today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on July 18, 2023 informing that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Consequently, Biotricity is now in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market.

Biotricity, Financial Results

Biotricity reports strong start to fiscal year 2024

July 6, 2023

Biotricity Inc. (Biotricity) today reported a strong start to its Fiscal Year 2024 ending March 31, 2024 and provided a preliminary estimate of its revenue for its first quarter of fiscal year 2024. For the first fiscal quarter ended June 30, 2023, the Company expects to report an approximate increase in revenue which represents growth of over 40% YOY from the corresponding prior year quarter and expects to achieve continued reduction in expenses.

Biotricity, News

Biotricity announces reverse stock split

June 30, 2023

Biotricity Inc. (Biotricity) today announced that it will effect a reverse stock split of its common stock. Biotricity expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on July 3, 2023. The reverse stock split was approved by the Board of Directors of the Company and is intended to increase the per share trading price of the Company’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Biotricity, News

Biotricity reaches $13M revenue run rate in April 2023 on accelerating growth

May 16, 2023

Biotricity Inc. (Biotricity) today reported that it reached a record $13 million annualized revenue run rate in April, further extending its growth by over eight percent from the $12 million run rate it announced for March 2023. In its Corporate Impact Report published earlier this month, Biotricity described both “better patient outcomes and substantial cost savings” for patients using its devices.